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ABSTRACT
Objective The gut–brain axis is considered as a major
regulatory checkpoint in the control of glucose
homeostasis. The detection of nutrients and/or hormones
in the duodenum informs the hypothalamus of the host’s
nutritional state. This process may occur via
hypothalamic neurons modulating central release of
nitric oxide (NO), which in turn controls glucose entry
into tissues. The enteric nervous system (ENS) modulates
intestinal contractions in response to various stimuli, but
the importance of this interaction in the control of
glucose homeostasis via the brain is unknown. We
studied whether apelin, a bioactive peptide present in
the gut, regulates ENS-evoked contractions, thereby
identifying a new physiological partner in the control of
glucose utilisation via the hypothalamus.
Design We measured the effect of apelin on electrical
and mechanical duodenal responses via telemetry probes
and isotonic sensors in normal and obese/diabetic mice.
Changes in hypothalamic NO release, in response to
duodenal contraction modulated by apelin, were
evaluated in real time with speciﬁc amperometric probes.
Glucose utilisation in tissues was measured with orally
administrated radiolabeled glucose.
Results In normal and obese/diabetic mice, glucose
utilisation is improved by the decrease of ENS/contraction
activities in response to apelin, which generates an
increase in hypothalamic NO release. As a consequence,
glucose entry is signiﬁcantly increased in the muscle.
Conclusions Here, we identify a novel mode of
communication between the intestine and the
hypothalamus that controls glucose utilisation. Moreover,
our data identiﬁed oral apelin administration as a novel
potential target to treat metabolic disorders.
INTRODUCTION
The gut–brain axis is of crucial importance in the
control of energy homeostasis. The detection or
‘sensing’ of intestinal lipids1 and glucose2 activates
extrinsic afferent nerves in the gut wall, which
inform the hypothalamus about the presence of
nutrients in the digestive tract. The subsequent
modulation of hypothalamic neuronal activity in
response to these peripheral signals leads to modiﬁ-
cation of metabolic functions including thermogen-
esis,3 food intake and glucose utilisation in tissues.4
Recent studies demonstrate the importance of
gut nutrient sensing in the control of glucose
homeostasis.5 Alteration of nutrient detection in
the duodenum and/or jejunum6 disturbs hypothal-
amic responses that could contribute to the estab-
lishment of increased hepatic glucose production7
Signiﬁcance of this study
What is already known on this subject?
▸ Circulating apelin is a bioactive peptide that
exerts pleiotropic actions in various organs
(brain, muscle, adipose tissue) to control
glucose utilisation and glycaemia.
▸ The gut-to-brain axis is of crucial importance in
the control of glucose homeostasis and is
profoundly altered during metabolic diseases
such as type 2 diabetes.
▸ Enteric nervous system (ENS) is under the
inﬂuence of various bioactive factors such as
leptin, which is able to be transcytosed from
the lumen to the gut wall.
What are the new ﬁndings?
▸ Luminal apelin is able to be transcytosed
through the intestine to reach intraduodenal
structures.
▸ Apelin controls ENS neurotransmitter release,
that is, acetylcholine and nitric oxide,
associated to variations of duodenal
contraction.
▸ Apelin triggers ENS-induced duodenal
contraction, leading to muscle glucose
absorption via hypothalamic relay.
▸ Chronic oral administration of apelin improves
glucose tolerance in closed correlation to a
decrease in duodenal motility in normal and
obese/diabetic mice.
How might it impact on clinical practice in
the foreseeable future?
▸ This study provides unequivocal evidences that
modulation of the ENS/contraction of the
duodenum is a new physiological system
controlling peripheral glucose utilisation via the
brain. More importantly, oral apelin
administration could be considered as a
promising therapeutic target to treat insulin
resistance state.
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and insulin resistance,2 characteristic features of type 2 diabetes.
The identiﬁcation of new molecular mechanisms that are able to
modify the gut–brain axis is of major signiﬁcance in discovering
new and successful therapeutic strategies. For example, leptin,
which is secreted in the luminal part of the intestine in response
to nutrients, can modify the activity of phosphatidylinositol 3
kinase in the jejunum to decrease hepatic glucose production.7
In addition to leptin, apelin is another potential target that
exerts pleiotropic effects in the whole body. Notably, apelin is
recognised as a bioactive peptide implicated in the control of
glucose metabolism.8 In the central nervous system (CNS),
apelin is a neurotransmitter able to target hypothalamic neurons
to control glycaemia.9 In the periphery, apelin is an adipokine
that improves insulin sensitivity of muscles from normal and
obese/diabetic mice.8 10 Recent data show that apelin is also
present and released in the luminal part of the intestine to
stimulate glucose absorption.11
In the GI tract, the enteric nervous system (ENS) is involved
in various physiological functions including modulation of intes-
tinal contraction. The ENS is essentially composed of excitatory
(choline acetyl transferase (ChAT)) motor neurons or inhibitory
motor neurons (neuronal nitric oxide synthase (nNOS)) that
stimulate or inhibit intestinal contractility and motility.12 These
ENS neurons are known to express receptors for various factors
such as leptin13 and glucagon-like peptide-2 (GLP-2).14 In the
later stage of diabetes, alterations of ENS in the proximal part
of the intestine (which is being affected ﬁrst) are associated with
an intestinal hypercontractility.12 Furthermore, several studies
have demonstrated that during diabetes there is a loss of inhibi-
tory neurons and an increase in cholinergic innervations in the
proximal part of the intestine.12 Whether the duodenum
contraction-controlled by ENS is implicated in the control of
glucose homeostasis via the brain is totally unknown.
Here, we investigate whether GI apelin can modify the activ-
ity of the ‘ENS/contraction’ couple to control whole-body
glucose utilisation via the brain. Overall, our study unravels a
new mode of communication involving the mechanical contract-
ility of the duodenum, which could be considered as a potential
therapeutic target to improve tissue glucose utilisation via the
brain during type 2 diabetes.
MATERIALS AND METHODS
Mice
Male C57BL/6J mice (Charles River Laboratory, l’Arbresle,
France) had free access to food and water. Mice were fed on
normal chow or high-fat diet (HFD) containing 20% protein,
35% carbohydrate and 45% fat (Research Diets, New
Brunswick, New Jersey, USA). These mice became obese and
insulin resistant after 3 months of HFD.9 Data have been
recorded in fed mice, corresponding to the phase where intes-
tinal segmental waves are generated to increase the rate of nutri-
ents absorption.15
Acute injections (apelin, apelin receptor (APJ) antagonist,
NOS inhibitor, agonist of β-adrenergic receptors, antagonist
of nicotinic receptors and capsaicin)
Protocol are described in online supplementary methods
section.
Chronic administration of apelin
In other experimental sets of mice, 100 mL of [Pyr]apelin-13 at
a concentration of 1 mM or 100 mL of H2O were orally loaded
(oral gavage), once a day for 1 week.
Intragastric and intracerebroventricular surgical procedures,
telemetry, isotonic contractions, immunohistochemistry,
transcytosis, acetylcholine release, glucose and apelin
absorption, glucose utilisation, qPCR, metabolic parameters,
insulin and apelin assays, oral glucose tolerance test
Protocols are described in online supplementary methods
section.
Cell culture and ﬂuorescence microscopy
HEK-293T cells were cultured as previously described16 to test
the functionality of apelin-TAMRA. Protocol is described in
detail in online supplementary methods section. Apelin-TAMRA
is a functional apelin molecule that is able to bind and activate
its receptor APJ (see online supplementary ﬁgure S1).
Ex vivo duodenal real-time NO measurement
Mice were euthanased in fed conditions. After dissection, duo-
denum fragments were washed in Krebs–Ringer bicarbonate/
glucose buffer (pH 7.4) in an atmosphere of 95% O2–5% CO2
and then immersed in Eppendorf tubes containing 400 mL of
the same medium. After a 10 min recovery period, the spontan-
eous NO release was measured at 37°C for 20 min by using an
NO-speciﬁc amperometric probe (ISO-NOPF, 100 mm diameter,
5 mm length, World Precision Instruments, Aston Stevenage,
UK) implanted directly in the duodenum. Data are expressed as
the change (delta) in NO release from basal conditions.9
In vivo hypothalamic real-time NO measurement
Mice in fed conditions were anesthetised with isoﬂurane. A 1 cm
midline incision was made across the top of the skull, and the
animal was placed on a stereotaxic apparatus, as described previ-
ously.6 Results are presented as mean±SEM. During ampero-
metric measurement, animals received H2O or drugs via an
intragastric injection of 10 mL/min rate for 10 min using a
syringe pump. We previously demonstrated that H2O is the
vehicle of choice for glucose administration.2 6 17 Furthermore,
we have also demonstrated that intragastric perfusion of H2O did
not modify c-Fos expression (a marker of neuronal activity) in
the hypothalamus compared with NaCl (0.9%). Therefore, all
control groups were infused with water, as previously described
in detail.2
Statistical analysis
The data are expressed as mean±SEM. Differences between the
experimental groups were assessed where appropriate using
unpaired Student’s and one-way or two-way analysis of vari-
ance, followed by post hoc Bonferroni test. Data were analysed
using GraphPad Prism V.5.00 for Windows (GraphPad Software,
San Diego, California, USA). The results were considered statis-
tically signiﬁcant at p<0.05.
RESULTS
Apelin acts on ENS neurons to control duodenal
contractions
The duodenum is the ﬁrst intestinal site of nutrient sensing5 and
apelin’s effect on glucose absorption.11 Using immunohisto-
chemistry, we found that the apelin receptor APJ is expressed
on ChAT and nNOS neurons (ﬁgure 1A). To determine whether
apelin is able to undergo transcytosis through the intestine, we
used apelin-TAMRA, a functional apelin molecule able to bind
to the apelin receptor APJ (see online supplementary ﬁgure S1).
We observed that apelin is able to reach underlying structures
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such as neuronal plexus (ﬁgure 1B), suggesting apelin, like other
adipokines such as leptin,18 undergo transcytosis.
To assess whether apelin is able to control duodenal motility
via the ENS, we used isotonic sensors to measure ex vivo mech-
anical contractions (see online supplementary ﬁgure S2A).
Validation of the technique was obtained by using
L-NG-nitroarginine methyl ester (L-NMMA) (an inhibitor of
NOS enzymes) and isoproterenol (an adrenergic receptor
agonist), which stimulated19 and inhibited20 intestinal contrac-
tions, respectively (see online supplementary ﬁgure S2B).
Application of apelin on ex vivo duodenal preparations
increased the amplitude of intestinal contractions (10 pM to
100 nM) (ﬁgure 2A) but did not affect the frequency of contrac-
tions (see online supplementary ﬁgure S2C). The effects of
apelin are speciﬁc to the duodenum since apelin did not modu-
late jejunum and ileum contractions (see online supplementary
ﬁgure S2D). However, concentrations of apelin >1 mM gener-
ated an amplitude of contraction proﬁle similar to that observed
at basal levels, suggesting the existence of a physiological switch
from a stimulatory effect (10 pM to 100 nM) to basal and/or
inhibitory state (1–10 mM) (ﬁgure 2A). This last result suggested
the existence of two different signalling pathways for the two
doses, and all these effects are antagonised by F13A (see online
supplementary ﬁgure S2E), an APJ receptor antagonist. To this
aim, we choose to focus our intention on the closest doses (ie,
100 nM and 1 mM) implicated in this physiological switch.
Stimulatory effect of apelin on intestinal contractions needed
ChAT neurons since hexamethonium, a nicotinic receptor
antagonist, blocked its effect (ﬁgure 2B). Moreover, stimulation
of duodenal contraction by apelin 100 nM is associated with an
increase of duodenal acetylcholine release (ﬁgure 2C) without
dose–effect (see online supplementary ﬁgure S3A), whereas NO
is not affected following the exposure to 100 nM of apelin
(ﬁgure 2D). Apelin 1 mM exerted the same effect than apelin
100 nM on duodenal acetylcholine release (ﬁgure 2C).
Conversely, apelin 1 mM increased real-time duodenal NO
release, indicating that this concentration of apelin is dependant
of nNOS neurons to modulate its effect on duodenal contrac-
tions (ﬁgure 2D). This effect was antagonised by the APJ antag-
onist F13A (see online supplementary ﬁgure S3B).
To assess whether this switch is observed in in vivo conditions,
we measured electrical duodenal activity in real time via a novel
method using electrodes surrounding the duodenum linked to
telemetric system (see online supplementary ﬁgure S3C). Apelin
was injected directly into the duodenum via an intragastric cath-
eter, whereby the electrical activity of the duodenum could be
closely associated to mechanical activity.21 We found that apelin
100 nM evoked a signiﬁcant increase in duodenal electrical activ-
ity, while apelin 1 mM decreased this activity (ﬁgure 2E). All
effects were abolished by APJ antagonist, demonstrating the spe-
ciﬁcity of apelin action (see online supplementary ﬁgure S3D).
Thus, apelin is able to modify duodenal contractions via a mech-
anism involving the ENS (ﬁgure 2F).
Duodenum and jejunum are the two parts of the proximal
intestine that both participate to the control of glucose absorp-
tion in various animal species.22 23 Duodenum also expresses
Figure 1 Apelin receptor (APJ) is expressed in enteric nervous system neurons. (A) Duodenal sections from mice stained with anti-APJ antibody
(left panels, green: white arrows), anti-choline acetyl transferase (ChAT) or anti-neuronal nitric oxide synthase (nNOS) antibodies (middle panels, red:
white arrows) and merge (right panels, yellow arrows). Pictures are representative of four mice per groups. Bars=10 mm. Right panel: schematic
representation of a transverse section through the duodenum. (B) Duodenal sections from mice perfused for 5 min with H2O (Control) (left panel) or
apelin-TAMRA (right panel). Apelin-TAMRA appears in red (red arrows). Pictures are representative of three mice per groups. Bars=10 mm.
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Figure 2 Apelin acts on the enteric nervous system to control duodenal contractions. (A) Ex vivo measurement of duodenal mechanical contraction
amplitude in response to Krebs–Ringer solution (Control) or increasing concentrations of apelin (1 pM to 10 mM). n=5–6 per group. *p<0.05 vs
Control. (B) Ex vivo measurement of duodenal mechanical contraction amplitude in response to Krebs–Ringer (Control), apelin 100 nM,
hexamethonium (Hx) 500 mM alone or with apelin 100 nM. n=5–6 per group. *p<0.05 vs Control. ##p<0.01, ###p<0.001. (C) Ex vivo measurement
of duodenal acetylcholine release in basal condition and in response to Krebs–Ringer (Control), apelin 100 nM or apelin 1 mM. n=4 per group.
*p<0.05. (D) Ex vivo measurement of duodenal nitric oxide (NO) release in response to Krebs–Ringer (Control), apelin 100 nM or apelin 1 mM.
n=5–8 per group. *p<0.05, **p<0.01, ***p<0.001 vs Control. #p<0.05, ##p<0.01, ###p<0.001 vs apelin 100 nM. (E) In vivo measurement of
duodenal electrical activity in response to H2O (Control), apelin 100 nM or apelin 1 mM. n=4–5 per group. *p<0.001 vs Control and versus apelin
1 mM. #p<0.001 vs Control and versus apelin 100 nM. (F) Schematic representation of the results: apelin modulates ENS activity causing a
modiﬁcation of duodenal contractions.
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intestinal glucose transporters and sensors.24–27 Previous studies
have shown that stimulation of intestinal motility is associated
with a rise in nutrient absorption.15 Our data show that apelin
100 nM increased duodenal glucose absorption as opposed to
apelin 1 mM (ﬁgure 3A). No signiﬁcant variation of apelin
absorption was observed in our experimental model (ﬁgure 3B),
but the level of apelin in the duodenum wall was signiﬁcantly
increased in apelin-treated duodenum fragments (see online
supplementary ﬁgure S6A). In in vivo conditions, gut apelin
instillation did not modify apelin concentrations in the portal
vein (ﬁgure 3C). These last results reinforce the concept of the
speciﬁc action of apelin in ENS on duodenal wall.
Duodenal apelin controls hypothalamic NO release
NO is a central hypothalamic actor that controls glucose
homeostasis.28 Moreover, alteration of intestinal glucose sensing
linked to the gut–brain axis is associated to abnormal NO hypo-
thalamic response in type 2 diabetes.6 Whether duodenal con-
tractions are able to modify hypothalamic NO release is
unknown. By using speciﬁc probes implanted in the hypothal-
amus of mice, we showed that decrease duodenal contraction by
isoproterenol leads to an increase of hypothalamic NO release
(see online supplementary ﬁgure S4A), demonstrating that intes-
tinal motility is able to control hypothalamic activity. Using the
same technique, gut administration of apelin 100 nM decreased
hypothalamic NO release while apelin 1 mM allowed a return to
basal NO levels (ﬁgure 4A). Importantly, this effect is blocked
by the APJ antagonist, F13A (see online supplementary ﬁgure
S4B, C). Moreover, blockade of nicotinic receptors with hexam-
ethonium or destruction of afferent nerve endings with capsa-
icin abolishes the effect of gut apelin on hypothalamic NO
release (ﬁgure 4B–D, see online supplementary ﬁgure S4D, E).
Here, our data prove the existence of a mode of communica-
tion between the gut and the brain, that is, duodenal contractil-
ity following apelin evoked signalling is able to modify
hypothalamic NO release (ﬁgure 4E).
Duodenal apelin controls muscle glucose utilisation via
hypothalamic NO
To measure the consequences of modiﬁcation of duodenal con-
tractions on glucose utilisation via the brain, we measured
glucose entry in different tissues in response to oral gavage of
apelin and radiolabeled glucose tracers in mice. Intragastric
apelin 100 nM decreased glucose entry in the muscle, but not in
liver nor in adipose tissue (ﬁgure 5A–C). Similar to the effects
observed on mechanical and electrical activities in the duode-
num, apelin 1 mM did not change basal glucose entry in the
muscle. To further investigate whether brain release of NO is
Figure 3 Apelin modulates duodenal glucose absorption. (A) Ex vivo glucose absorption in duodenal everted sacs in response to Krebs–Ringer
(Control), apelin 100 nM, apelin 1 mM, F13A alone or with apelin 100 nM. n=5–7 per group. *p<0.05, **p<0.01. (B) Ex vivo apelin absorption in
duodenal everted sacs in response to Krebs–Ringer (Control), apelin 100 nM or 1 mM, and F13A alone or F13A plus apelin 100 nM. n=4–6 per
group. (C) In vivo measurement of plasma apelin in portal vein, in response to oral gavage of H2O (Control), apelin 100 nM or apelin 1 mM. n=5–6
per group.
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mechanistically involved in the effect observed following intra-
gastric apelin 1 mM treatment on glucose muscle entry, we have
blocked NO release in the brain by using intracerebroventricular
injection of L-NMMA. We found that blocking NO release in
the brain decreases glucose entry in the muscle (see online
supplementary ﬁgure S5A–C), thereby showing the key role of
brain NO on the apelin-gut to brain to muscle axis.
Together, our data show that apelin 100 nM increases duo-
denal contractility and decreases muscle glucose utilisation
(ﬁgure 5D) via a hypothalamic NO relay.
Chronic apelin gavage increases glucose tolerance via a
decrease in duodenal motility
We hypothesised that a chronic stimulation by high level of
apelin could provoke a decrease in duodenal contractility and
could be associated with an improved glucose tolerance. To test
whether chronic apelin treatment could modify basal duodenal
contractility, and subsequently glucose utilisation, we measured
basal mechanical activity in the duodenum of mice orally
treated with apelin (1 mM) for 1 week. Here, we show that
chronic oral treatment with apelin increased apelin
Figure 4 Duodenal apelin controls the gut motility-to-brain axis. (A) In vivo effect of intragastric perfusion of H2O (Control), apelin 100 nM or
apelin 1 mM, on nitric oxide (NO) hypothalamic release frequency. n=5–7 per group. **p<0.01 vs Control. (B) In vivo effect of intragastric perfusion
of H2O (Control), apelin 100 nM, hexamethonium (Hx) 500 mM alone or with apelin 100 nM, on NO hypothalamic release frequency. n=5–8 per
group. *p<0.01, ***p<0.001 vs Control. ###p<0.001 vs apelin 100 nM. (C) In vivo effect of intragastric perfusion of H2O (Control), apelin 1 mM, Hx
500 mM alone or with apelin 1 mM, on NO hypothalamic release frequency. n=5–8 per group. ***p<0.001 vs Control. ###p<0.001 vs apelin 1 mM.
(D) In vivo effect of intragastric perfusion of H2O (Control) and apelin 100 nM in mice pretreated or not by capsaicin on NO hypothalamic release
frequency. n=4–7 per group. *p<0.01, ***p<0.001 vs Control. ###p<0.001 vs apelin 100 nM. (E) Schematic representation of the results: by
modifying duodenal contractility, apelin modulates NO hypothalamic release.
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concentration in the duodenum, but not in the jejunum and
ileum; this observation reinforces the fact that the duodenum is
a major target of transcytosed apelin (see online supplementary
ﬁgure S6B). Chronic apelin treatment decreased basal duodenal
contractility (ﬁgure 6A), increased glucose tolerance (ﬁgure 6B)
and insulin release in response to glucose (ﬁgure 6C).
Moreover, this was associated with an increase of glucose trans-
porter type 4 (GLUT 4) mRNA expression (ﬁgure 6D) and
glucose entry in the muscle (ﬁgure 6E). No signiﬁcant variation
was observed regarding glucose entry in the liver and adipose
tissue (see online supplementary ﬁgure S6C, D). This improve-
ment of glucose tolerance was not associated to modiﬁcation of
body weight (control=25.2±0.8 g vs apelin 1 mM=23.3
±0.9 g).
Apelin restores normal duodenal motility and improves
glucose tolerance in obese/diabetic mice
Similar to that observed in plasma and various tissues (eg,
adipose tissue, muscle), we show that apelin mRNA level was
signiﬁcantly increased in the duodenum of HFD mice, but not
in the jejunum and in the ileum (see online supplementary
ﬁgure S7A). APJ mRNA expression was not modiﬁed in the
proximal part of the intestine in HFD mice compared with
control mice (see online supplementary ﬁgure S7B). First, we
measured duodenal contraction in HFD mice in response to
acute apelin 1 mM. We found that apelin 1 mM counterbalanced
the hypercontractility of duodenum generated by HFD
treatment in ex vivo and in vivo conditions (ﬁgure 7A, B and
online supplementary ﬁgure S7C). This effect was associated
with an increase of duodenal NO release (ﬁgure 7C) similar to
that observed in normal mice (ﬁgure 2D). Then, the decrease of
duodenal contractility is correlated with, ﬁrst, a decrease intes-
tinal glucose absorption (ﬁgure 7D), without effect on apelin
absorption (ﬁgure 7E), and second, an increase in hypothalamic
NO release in HFD apelin-treated mice (ﬁgure 7F and online
supplementary ﬁgure S7D). This modulation of gut–brain axis
by apelin is associated with an improved glucose utilisation in
muscle (ﬁgure 7G–I).
To test whether targeting the duodenal motility via apelin
could be considered as a potential therapeutic target to treat
type 2 diabetes, we measured the impact of a chronic (1 week)
oral gavage of apelin in HFD mice. First, we found that chronic
oral apelin administration improved fed glycaemia, fasted insuli-
nemia and homeostasis model assessment insulin resistance of
HFD mice (ﬁgure 8A). Second, chronic oral apelin treatment
decreased basal duodenal motility (ﬁgure 8B) associated with an
improved glucose tolerance (ﬁgure 8C) and insulin resistance
index (ﬁgure 8D) in HFD mice. Third, chronic apelin treatment
increased GLUT4 mRNA expression in the muscle (ﬁgure 8E).
DISCUSSION
Circulating apelin is well recognised as a factor involved in the
control of glucose homeostasis by modulating glucose utilisation
acting directly on tissues (adipose tissue, muscle, intestine). In
Figure 5 Duodenal apelin modulates muscle glucose utilisation. In vivo measurement of glucose entry in liver (A), muscle (B) and adipose tissue
(C) in response to oral gavage of radiolabeled glucose in combination with H2O (Control), apelin 100 nM alone or with F13A, apelin 1 mM alone or
with F13A and F13A alone. n=9–11 per group. *p<0.05 vs Control and versus F13A. #p<0.01 vs apelin 1 mM and versus apelin 1 mM+F13A.
$p<0.001 vs apelin 100 nM+F13A. (D) Schematic representation of the results: duodenal apelin controls muscle glucose utilisation via a
hypothalamic relay.
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the brain, apelin exerts a dual effect depending on the nutri-
tional state and its levels present in the hypothalamus. We have
previously demonstrated that low dose of apelin administrated
intracerebroventricularly improves glycaemia in fed mice.9 This
effect could be linked to the slight and continuous increase in
plasma apelin observed during the dark period (corresponding
to the fed state). All these data suggest that a physiological rise
of apelin in the whole body exerts beneﬁcial effect on glucose
metabolism as previously observed after an acute intravenous
injection.10 Here, we show that apelin has a dual effect on ENS
neurons similar to that observed in the CNS. In particular, we
show that apelin induces modulations of duodenal contractility
and subsequently modiﬁes hypothalamic activity via variations
of hypothalamic NO release to control muscle glucose utilisa-
tion. Thus, a parallel could be made between apelin’s action on
ENS and CNS neurons. In the brain, the effects of apelin on
hypothalamic-releasing factors are different depending on the
dose administered. Low dose of apelin stimulates NO release,
while central high dose of apelin (which has deleterious action
on glucose metabolism9) releases hydrogen peroxide instead of
NO.29 In the duodenum, a similar differential effect on NO
release is observed, suggesting that the recruitment of duodenal
nNOS neurons in response to apelin is dependent on the dose
injected. In fact, apelin is able to stimulate acetylcholine release
at 100 nM and 1 mM, but this potential stimulatory effect of
apelin on duodenal contractions is counterbalanced by the
action of apelin 1 mM on duodenal NO release. For these
reasons, apelin 1 mM effect on duodenal contractions is similar
to control in normal mice. This hypothesis is supported by data
obtained in HFD mice since apelin 1 mM stimulates duodenal
NO release to decrease duodenal hypercontractility. We cannot
totally rule out the possibility that apelin 1 mM exerts downre-
gulation of APJ expression in our experimental models similar
to that observed in the hypothalamus of obese rats,30 but our
data tend to limit this possibility. First, we show that apelin
mRNA expression is increased in the duodenum of HFD mice,
without modiﬁcation of APJ mRNA expression. This result sup-
ports data from the literature, suggesting that peripheral increase
expression of apelin could represent an adaptive pathway to
counterbalance insulin resistance.8 Second, duodenal fragments
release NO in response to apelin 1 mM, but not 100 nM,
reinforcing the existence of two different molecular actors to
respectively block and stimulate duodenal contractions. Then,
our data suggest that ENS neurons are potential targets of
Figure 6 Chronic oral gavage of apelin 1 mM increases glucose tolerance via a decrease in duodenal contractility. (A) Ex vivo measurement of
duodenal mechanical contraction in mice orally gavaged for 1 week with H2O (Control) or apelin 1 mM. n=4–5 per group. *p<0.05 vs Control. (B)
Oral glucose tolerance test (OGTT) in 6 h fasted mice, orally gavaged for 1 week with H2O (Control) or apelin 1 mM. n=4–5 per group. *p<0.05,
***p<0.001 vs Control. The adjacent graph represents the average area under the curve. (C) OGTT-associated insulinemia in 6 h fasted mice, orally
gavaged for 1 week with H2O (Control) or apelin 1 mM. n=4–5 per group. *p<0.05. (D) Relative expression of glucose transporter type 4 mRNA in
muscle of mice orally gavaged for 1 week with H2O (Control) or apelin 1 mM. n=9–10 per group. *p<0.05 vs Control. (E) In vivo measurement of
glucose entry in muscle in response to oral gavage of radiolabeled glucose, in mice orally gavaged for 1 week with H2O (Control) or apelin 1 mM.
n=7 per group. **p<0.01 vs Control.
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apelin action on duodenal motility since (1) apelin modulates
duodenal acetylcholine and NO release, (2) apelin stimulatory
effect is blocked by hexamethonium and (3) apelin receptor APJ
is expressed on ENS neurons. As apelin receptor APJ is
expressed in the intestinal wall, we can speculate that apelin
may also exert effects on other intestinal cells. Thus, we cannot
exclude the potential existence of a direct action of apelin on
intestinal smooth muscles.
In the present study, we proposed a new and physiologically
relevant mode of communication between the gut and the brain
that controls glucose utilisation. Speciﬁcally, our data suggest
that peripheral glucose utilisation can be controlled by duodenal
contractility via a hypothalamic relay. In physiological condi-
tions, our data suggest that apelin exerts differential effect on
ENS neurons during digestion. Therefore, we propose the fol-
lowing model, at the beginning of food intake, apelin has a
stimulatory effect (1) on intestinal glucose absorption via
actions on GLUT2 translocation11 and (2) on duodenal motility.
This stimulatory effect on intestinal contraction leads to a hypo-
thalamic NO blockade that decreases glucose utilisation in
tissues in order to avoid a potential hypoglycaemia. At the end
of the meal, high levels of apelin target nNOS neurons to (1)
slow down duodenal waves and stop glucose absorption, (2)
restore hypothalamic NO release and (3) increase muscle
Figure 7 Apelin 1 mM decreases duodenal contractility and improves glucose utilisation in obese/diabetic mice. (A) Ex vivo measurement of
duodenal mechanical contraction amplitude in response to Krebs–Ringer (Control) (in normal chow or high-fat diet (HFD) mice) and apelin 1 mM (in
HFD mice). n=5–6 per group. *p<0.05. (B) In vivo measurement of duodenal electrical activity in response to H2O (Control HFD) and apelin 1 mM.
n=4–7 per group. ***p<0,001 vs Control HFD. (C) Duodenal nitric oxide (NO) release in response to Krebs–Ringer (Control HFD) or apelin 1 mM.
n=4–7 per group. *p<0.05, **p<0.01 vs Control HFD. (D) Ex vivo glucose absorption in duodenal everted sacs in response to Krebs–Ringer (Control
HFD) and apelin 1 mM. n=4–6 per group. *p<0.05 vs Control HFD. (E) Ex vivo apelin absorption in duodenal everted sacs in response to Krebs–
Ringer (Control HFD) and apelin 1 mM. n=6 per group. (F) In vivo effect of intragastric perfusion of H2O (Control HFD) and apelin 1 mM on NO
hypothalamic release frequency. n=6 per group. **p<0.01 vs Control HFD. In vivo measurement of glucose entry in liver (G), muscle (H) and
adipose tissue (I) in response to oral gavage of radioactive glucose in combination with H2O (Control HFD) and apelin. n=4–6 per group. *p<0.05
vs Control HFD.
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glucose utilisation. The association between central NO and per-
ipheral glucose utilisation has been previously demonstrated by
our group since an increase in hypothalamic NO release stimu-
lates peripheral vascular ﬂux, leading to glucose entry in
muscle.28
Such regulations of glucose homeostasis implicating the gut–
brain axis and an intestinal sensor during the digestion have
clearly been established. We have previously demonstrated that
intestinal glucose sensing during hyperglycaemia generates an
increase in hepatic glycogenesis to prevent the next period of
fasting via a central relay.17 This phenomenon implicates a
hypothalamic GLP-1 pathway; GLP-1 is, similar to apelin, an
intestinal hormone present in the brain and playing an
important role as a neurotransmitter.2 All these data implicating
intestinal hormonal sensing and mechanosensing highlight the
importance of the ‘gut-to-brain-to-peripheral’ axis in the control
of glucose metabolism.
Type 2 diabetes is associated with insulin resistance. We have
previously demonstrated that alteration of intestinal glucose
sensing participates to the insulin resistance state observed in
obese/diabetic mice.2 6 In fact, intestinal inﬂammation and oxi-
dative stress are associated with abnormal glucose sensing,
leading to aberrant hypothalamic NO release.6 This alteration
of glucose detection could be associated with disturbance of
mechanodetection. Accordingly, it has been shown that type 2
diabetes is associated with a decrease of nNOS neuronal
Figure 8 Apelin 1 mM treatment increases glucose tolerance via a decrease in duodenal contractility. (A) Effects of high-fat diet (HFD) on
metabolic parameters in mice orally gavaged for 1 week with H2O (Control HFD) or apelin 1 mM. n=6 per group. (B) Ex vivo measurement of
duodenal mechanical contraction in HFD mice orally gavaged for 1 week with H2O (Control HFD) or apelin 1 mM. n=6 per group. **p<0.01 vs
Control HFD. (C) Oral glucose tolerance test (OGTT) in 6 h fasted HFD mice, orally gavaged for 1 week with H2O (Control HFD) or apelin 1 mM. n=6
per group. **p<0.01, ***p<0.001 vs Control HFD. The adjacent graph represents the average area under the curve (AUC). (D) OGTT-associated
insulin resistance index in 6 h fasted HFD mice, orally gavaged for 1 week with H2O (Control HFD) or apelin 1 mM. n=6 per group. *p<0.05 vs
Control HFD. (E) Relative expression of glucose transporter type 4 (GLUT-4) mRNA in muscle of HFD mice orally gavaged for 1 week with H2O
(Control HFD) or apelin 1 mM. n=9–10 per group. *p<0.05 vs Control. HOMA-IR, homeostasis model assessment insulin resistance; NC, normal
chow.
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population in the ENS12 generating an increase of intestinal
motility.12 31 Intestinal hypermotility could ﬁrst induce an
increase in duodenal glucose absorption, leading to fed hyper-
glycaemia, and second, according to our results, it may cause
insulin resistance via the brain. Here, we have shown that high
levels of apelin are able to restore basal duodenal contraction,
speciﬁcally in the proximal portion of the intestine in normal
and obese/diabetic mice. Targeting the ENS neurons to modu-
late gut contraction via apelin or another molecular target repre-
sents an invaluable tool to decrease duodenal contraction,
which could have a real potential interest for new therapeutic
strategies to treat type 2 diabetes comorbidities such as hyper-
glycaemia and insulin resistance. Our data support this hypoth-
esis since chronic oral apelin ameliorates glucose tolerance in
HFD mice.
Numerous factors could reach the ENS neurons to modulate
their activities. Some of them could have a plasma origin, and
others could act from the intestinal lumen to the ENS via transcy-
tosis as in the case of leptin.18 Apelin is known to be released in
the lumen by enterocytes in response to glucose to aid glucose
absorption.11 In this study, we show that transcytosis of apelin in
the duodenum controls glucose absorption via an ENS-dependent
mechanism. Therefore, our data highlight a novel mode of regula-
tion of glucose homeostasis involving an intestinal factor. The
importance of gut hormones such as GLP-1 in the control of
glucose metabolism is well established32 and represents an innova-
tive approach to treat metabolic disorders. In addition to their
direct effects on insulin-sensitive tissues, the potential actions of
these factors on ‘ENS/contraction-to brain-to peripheral’ axis
could bring new possibilities and combinations to improve diabetic
state. Actually, type 2 diabetic strategies aim to target GLP-1,
which is released by L-cells located in the ileum. Another original-
ity of our work is to target the ﬁrst site of nutrients detection, that
is, the duodenum, which is now considered, like jejunum,7 as a
future target to restore glucose homeostasis during diabetes.5
Nutrient sensing, which is largely altered in type 2 diabetes,5
could be compensated by modulation of duodenal contraction as a
therapeutic action to suppress hyperglycaemia. This hypothesis is
supported by the work of Sandoval et al,33 which demonstrates
that internal mechanical manipulation of the duodenum after
fasting generates gut hormones release. We speculate that modula-
tion of intestinal contractions by apelin or other factors could
involve a hormonal-mediated signal in addition to the capsaicin-
sensitive afferent nervous signal demonstrated in the present study.
In conclusion, we provide evidence that interactions between
the ENS, duodenal contractility and the brain are of crucial
importance to control glucose utilisation in physiological condi-
tions. Moreover, we demonstrate that intestinal apelin is a key
actor playing a major role in this system. Besides, numerous pos-
sibilities exist in terms of (1) potential other molecular factors
(eg, hormones) targeting this system or (2) potential effects on
physiological functions (eg, food intake, lipid metabolism); our
study illustrates the mechanisms of action of intestinal apelin
and its impact on glucose homeostasis. Future explorations are
warranted to demonstrate the role of this axis to treat metabolic
diseases in humans.
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